Wyeth kills off Solvay pact

Following bifeprunox's FDA rejection in August, Wyeth has opted out of its development deal with Solvay. In order to gain approval, the FDA told Wyeth and Solvay that they must run another trial and present more data before the agency would reconsider approval. Apparently Wyeth wanted no part in that. The company is returning rights to bifeprunox, as well as several other drug candidates. Wyeth and Solvay first announced their partnership in 2004 and then expanded it in 2007 to include research in neuroscience.

According to Wyeth's statement, the company "terminated the collaboration with Solvay after assessing the opportunity for bifeprunox and determining it would not have sufficient commercial value for the two companies to share."

- see this release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.